Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05098171
Other study ID # GC201-1.0
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date September 26, 2021
Est. completion date September 25, 2025

Study information

Verified date April 2024
Source Shanghai Juncell Therapeutics
Contact Clinical GC
Phone 086-18001759113
Email clinicaltrials@juncell.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 25, 2025
Est. primary completion date September 25, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age: 18 years to 75 years; 2. Histologically diagnosed as primary/relapsed/metastasized Gynecological tumors; 3. Expected life-span more than 3 months; 4. Karnofsky=60% or ECOG score 0-2; 5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available. 6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated; 7. At least 1 evaluable tumor lesion; 8. Hematology and Chemistry(within 7 days prior to enrollment): - Absolute count of white blood cells=2.5×10^9/L; - Absolute count of neutropils=1.5×10^9/L; - Absolute count of lymphocytes =0.7×109/L; - Platelet count=100×10^9; - hemoglobin=90 g/L; - Activated partial thromboplastin time (APTT) =1.5xULN (Unless received anticoagulant therapy within the previous 3 days); - International normalized ratio (INR) =1.5xULN (Unless received anticoagulant therapy within the previous 3 days); - Serum creatinine =1.5mg/dL(or =132.6µmol/L), or clearance rate=50mL/min; - Serum ALT/AST =3×ULN(subjects with liver metastasis =3×ULN); - Totol bilirubin=1.5×ULN; 9. no absolute or relative contraindications to operation or biopsy; 10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion; 11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs; 12. Be able to understand and sign the informed consent document; 13. Be able to stick to follow-up visit plan and other requirements in the agreement. Exclusion Criteria: 1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment; 2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%; 3. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc. 4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive; 5. Severe physical or mental diseases; 6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection); 7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy; 8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy; 9. Having received immunotherapy and developed irAE level greater than Level 3; 10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded); 11. Females in pregnancy or lactation; 12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy; 13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

Study Design


Intervention

Biological:
Signal Switch Receptor Modified TIL
Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.

Locations

Country Name City State
China Shanghai Tenth People's Hospital Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Juncell Therapeutics Shanghai 10th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events (AE) To characterize the safety profile of Signal Switch Receptor Modified TIL (GC201 TIL) in patients with advanced gynecologic tumors as assessed by incidence of adverse events related to GC201 TIL infusion. Up to 6 months
Primary Objective Response Rate (ORR) Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1):
ORR (proportion of patients) = # with CR + # with PR / # with CR + # with PR + # with SD + # with PD.
( Except baseline evaluation within 28 days before TIL infusion,PET/CT scan will be performed at 6 weeks after GC201 TIL infusion, and than every 6 weeks for 6 months, and then every 6 months after that for up to 3 years)
Up to 36 months
Primary Disease Control Rate (DCR) Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1: DCR (proportion of patients) = # with CR + # with PR + # with SD / # with CR + # with PR + # with SD + # with PD. Up to 36 months
Primary Duration of Response (DOR) The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1 Up to 36 months ]
Primary Progression-Free Survival (PFS) The time length between GC201 TIL infusion and confirmed subsequent disease progression according to RECIST 1.1 Up to 36 months
Primary Overall Survival (OS) The length of time from the date of the start of GC201 TIL treatment that the patients are still alive Up to 36 months ]
Secondary Change in Quality of Life Comparison of patients' quality of life before and after GC201 TIL treatment as assessed by the EORTC QLQ-30 (V3.0). Up to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05098197 - Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers Early Phase 1
Recruiting NCT05098184 - Study on TIL for the Treatment of Advanced Melanoma Early Phase 1
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT06057350 - Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR N/A
Recruiting NCT05084625 - PACED-digitized Support During Adjuvant Endocrine Therapy N/A
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Recruiting NCT05142475 - Study on TIL for the Treatment of Advanced Breast Cancer Early Phase 1
Completed NCT04913350 - Contralateral Effects of Russian Current on Adolescent Athlete N/A
Terminated NCT04004884 - Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
Recruiting NCT04768582 - Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients N/A
Recruiting NCT05767866 - Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR Phase 1/Phase 2
Recruiting NCT06340516 - NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity N/A
Recruiting NCT06315582 - Surgical Approach to Uterine Septum N/A
Recruiting NCT05468307 - Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors Early Phase 1
Not yet recruiting NCT05085808 - RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) Phase 4
Recruiting NCT04923100 - Therapeutic Effect of New Biologics in Crohn's Disease
Recruiting NCT05446051 - Development and Testing of a TTDSS for Cancer Patients N/A
Recruiting NCT05030701 - Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
Recruiting NCT05492487 - A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore Phase 2